Table 1.
Cohort baseline characteristics and neutralizing antibody responses to SARS-CoV-2 vaccination and COVID-19 infection.
| Vaccination cohort | Infection cohort | ||||||
|---|---|---|---|---|---|---|---|
| Patients, n | 42 | 21 | |||||
| Age (years) | 63 ± 10 (42–82) | 62 ± 9 (41–80) | |||||
| Women, n (%) | 11 (26%) | 8 (38%) | |||||
| Race | African American, n (%) | 32 (76%) | 17 (81%) | ||||
| White, n (%) | 8 (19%) | 3 (14%) | |||||
| Asian, n (%) | 2 (5%) | 1 (5%) | |||||
| Vaccination Status | n = 26: MOD-MOD-MOD (0.5 ml) n = 16: MOD-MOD-MOD (0.25 ml) |
3 unvaccinated; 2 BNT-BNT; 5 MOD-MOD; 11 MOD-MOD-MOD |
|||||
| COVID Hospitalization, n (%) | Not appliable | 3 (14%) | |||||
| COVID Mortality, n (%) | Not appliable | 1 (5%) | |||||
| Titer Calculations | |||||||
|
nAb titer
before third MOD |
Peak nAb titer
after third MOD |
Time-to-peak after third MOD (days) |
nAb Half-life
(days) |
nAb titer
pre-COVID-19 (20 patients) |
nAb titer
post-COVID-19 (17 patients) |
||
| WT | Geometric mean | 126 | 2,248 | 23 | 65 | 205 | 2,458 |
| 95% CI | 43–237 | 1,788–6,711 | 11–28 | 57–75 | 73–574 | 928–6,511 | |
| Omicron | Geometric mean | 4 | 84 | 24 | 51 | 7 | 273 |
| 95% CI | 1–12 | 50–319 | 11–78 | 41–68 | 3–17 | 135–553 | |
Neutralizing antibody (nAb) titer is presented as sVNT50 (surrogate virus neutralization titer at 50%). MOD, Moderna mRNA1273; BNT, Pfizer–BioNTech BNT162b2; CI, confidence interval. Age is shown as mean ± standard deviation.